1-10 of 10
Maral DerSarkissian
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Real-World Drug Adherence, Persistence, and Healthcare Resource Utilization in Patients with Paroxysmal Nocturnal Hemoglobinuria in the USA: The Advantage Study

Elizabeth A. Griffiths, Andrew Messali, Mohammed Mahdi, Maral DerSarkissian, Rose Chang, Brendan Rabideau, David Dingli
Journal: Blood
Blood (2024) 144 (Supplement 1): 5074.
https://doi.org/10.1182/blood-2024-203329
Published: 2024
Journal Articles

Comparative Effectiveness of Lenalidomide/Dexamethasone-Based Triplet Regimens for Treatment of Relapsed and/or Refractory Multiple Myeloma in Subgroups Defined By Cytogenetic Risk

Larysa Sanchez, Mu Cheng, Dasha Cherepanov, Maral DerSarkissian, Dawn Marie Stull, Fei Huang, Annalise Hilts, Justin Chun, Mei Sheng Duh, Sikander Ailawadhi
Journal: Blood
Blood (2022) 140 (Supplement 1): 4308–4309.
https://doi.org/10.1182/blood-2022-156320
Published: 2022
Journal Articles

Comparing Acalabrutinib and Ibrutinib in the Real World: A Study of 2,509 Patients with Chronic Lymphocytic Leukemia

Lindsey E. Roeker, Maral DerSarkissian, Kellie J. Ryan, Yan Chen, Svea K. Wahlstrom, Shweta Hakre, Louise Yu, Helen Guo, Anthony R. Mato
Journal: Blood
Blood (2022) 140 (Supplement 1): 4156–4158.
https://doi.org/10.1182/blood-2022-167213
Published: 2022
Journal Articles

Real-World Treatment Patterns and Clinical Outcomes with Brentuximab Vedotin or Other Standard Therapies in Patients with Previously Treated Cutaneous T-Cell Lymphoma (CTCL): A Retrospective Chart Review Study in the United States

Stefan K. Barta, Nicholas Liu, Maral DerSarkissian, Rose Chang, Mingchen Ye, Mei Sheng Duh, Andy Surinach, Michelle A. Fanale, Kristina S. Yu
Journal: Blood
Blood (2022) 140 (Supplement 1): 5167–5169.
https://doi.org/10.1182/blood-2022-162375
Published: 2022
Journal Articles

Treatment Patterns and Outcomes of Patients with Double-Class Refractory or Triple-Class Refractory Multiple Myeloma: A Retrospective US Electronic Health Record Database Study

Feng Wang, Boris Gorsh, Maral DerSarkissian, Prani Paka, Rachel Bhak, Natalie Boytsov, Miriam L. Zichlin, Leah Sansbury, Christopher W. Yee, Shannon Ferrante, Anamika Khanal, Ahmed Noman, Mei Sheng Duh
Journal: Blood
Blood (2021) 138 (Supplement 1): 2705.
https://doi.org/10.1182/blood-2021-152301
Published: 2021
Journal Articles

Time and Personnel Costs Associated with Adverse Event (AE) Management Among Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Acalabrutinib, Ibrutinib, or Venetoclax

Hetalkumari Patel, Svea K. Wahlstrom, Maral DerSarkissian, Colin Kunzweiler, Felicia Castriota, Rose Chang, Hoi Ching Cheung, Yuqian Gu, Helen Guo, Mei Sheng Duh, Kellie J. Ryan
Journal: Blood
Blood (2021) 138 (Supplement 1): 2999.
https://doi.org/10.1182/blood-2021-147449
Published: 2021
Journal Articles

Treatment Characteristics and Deep Molecular Response in Chronic Phase - Chronic Myeloid Leukemia Patients Treated with Second-Line Nilotinib or Dasatinib: A Multi-Country Retrospective Chart Review Study

Jorge E. Cortes, MD, Lynn Huynh, Estella Mendelson, PhD, Patricia Brandt, PhD, Darshan Dalal, MPH, MD PhD, Maral Dersarkissian, PhD, Diego Cortina, MD MSc, Sahil Narkhede, BA, Mei Sheng Duh, MPH, ScD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2897.
https://doi.org/10.1182/blood.V130.Suppl_1.2897.2897
Published: 2017
Journal Articles

Cost Offsets in the Treatment Journeys of Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Sikander Ailawadhi, Maral DerSarkissian, PhD, Mei Sheng Duh, MPH, ScD, Marie-Hélène Lafeuille, MA, George Posner, BA, Stephen Ralston, PhD, Erin Zagadailov, PharmD, MS, Abbie Ba-Mancini, MSc, MBA, Robert M Rifkin, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 5599.
https://doi.org/10.1182/blood.V130.Suppl_1.5599.5599
Published: 2017
Journal Articles

A Meta-Analysis and Meta-Regression of the Efficacy of Front-Line Treatment Combinations with Ponatinib Versus 1st- and 2nd-Generation Tyrosine Kinase Inhibitors for Ph+ Acute Lymphoblastic Leukemia

Elias J. Jabbour, MD, Maral DerSarkissian, PhD, Mei Sheng Duh, Nora McCormick, MSc, Wendy Y. Cheng, MPH, MPhil, Lisa J. McGarry, MPH, Ariadne Souroutzidis, BA, Hui Huang, PhD MBA, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2016) 128 (22): 5189.
https://doi.org/10.1182/blood.V128.22.5189.5189
Published: 2016
Journal Articles

The Impact of Ponatinib Versus Allogeneic Stem Cell Transplant (SCT) on Outcomes in Patients with Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) with the T315I Mutation

Franck E. Nicolini, MD PhD, Grzegorz W. Basak, MD PhD, Dong-Wook Kim, MD PhD, Eduardo Olavarria, MD PhD, Javier Pinilla-Ibarz, MD PhD, Jane F. Apperley, MD, Timothy P. Hughes, MD, Dietger Niederwieser, MD, Michael J. Mauro, MD, Charles Chuah, MD PhD, Andreas Hochhaus, MD, Giovanni Martinelli, MD PhD, Maral DerSarkissian, PhD, Andrew Kageleiry, BS, Mo Yang, PhD, Hui Huang, MBA, PhD, Lisa J. McGarry, MPH, Hagop M. Kantarjian, MD, Jorge E. Cortes, MD
Journal: Blood
Blood (2015) 126 (23): 480.
https://doi.org/10.1182/blood.V126.23.480.480
Published: 2015